grant
Project 1: Exploring viral and immunological factors of HPV associated cancers in PLWH and its relation to survival
Organization H. LEE MOFFITT CANCER CTR & RES INSTLocation TAMPA, UNITED STATESPosted 3 Aug 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAfrica South of the SaharaAgeAnalAnal CancerAnusAnus CancerAutomobile DrivingB7-H1Body TissuesCD152CD152 AntigenCD152 GeneCD274CD3CD3 AntigensCD3 ComplexCD3 moleculeCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCTLA 4CTLA-4 GeneCTLA4CTLA4 geneCTLA4-TMCancer BurdenCancer TreatmentCancersCausalityCell BodyCellsCervicalCervical CancerCervix CancerClinicalCountryCytotoxic T-Lymphocyte Protein 4Cytotoxic T-Lymphocyte-Associated Antigen 4Cytotoxic T-Lymphocyte-Associated Protein 4Cytotoxic T-Lymphocyte-Associated Serine Esterase-4DNADeoxyribonucleic AcidDevelopmentEnrollmentEnvironmentEtiologyExclusionFOXP3FOXP3 geneForkhead Box P3FrequenciesFutureGene TranscriptionGenetic TranscriptionGenotypeGoalsGroupingHIVHPVHPV caused cancerHPV driven cancersHPV induced cancerHPV malignancyHPV+ cancerHPV-Related MalignancyHPV-associated cancerHPV-associated malignancyHPV-related cancerHuman Immunodeficiency VirusesHuman Papilloma VirusHuman Papilloma Virus-Related MalignancyHuman Papilloma Virus-Related Malignant NeoplasmHuman Papilloma Virus-associated cancerHuman Papilloma Virus-associated malignancyHuman Papilloma Virus-related cancerHuman PapillomavirusHuman papillomavirus cancerHuman papillomavirus induced cancerHuman papillomavirus malignancyHuman papillomavirus-Related MalignancyHuman papillomavirus-Related Malignant NeoplasmImmuneImmune infiltratesImmune mediated therapyImmunesImmunityImmunologic FactorsImmunological FactorsImmunologically Directed TherapyImmunotherapyIncidenceIndividualInfectious Human Wart VirusInfiltrationInfrastructureInvestigationJM2LAV-HTLV-IIILMICLYT3LaboratoriesLymphadenopathy-Associated VirusMalignant Anal NeoplasmMalignant Anal TumorMalignant Cervical NeoplasmMalignant Cervical TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant Neoplasm of the CervixMalignant NeoplasmsMalignant Oropharyngeal NeoplasmMalignant Oropharyngeal TumorMalignant Penile TumorMalignant TumorMalignant Tumor of the AnusMalignant Tumor of the CervixMalignant Tumor of the Cervix UteriMalignant Uterine Cervix NeoplasmMalignant Uterine Cervix TumorMalignant Vulva TumorMalignant Vulvar NeoplasmMalignant Vulvar TumorMalignant neoplasm of anusMalignant neoplasm of cervix uteriMalignant neoplasm of penisMalignant neoplasm of vulvaMedicalMethodsNational Cancer BurdenNon-Polyadenylated RNAOKT3 antigenOncogenicOncologyOncology CancerOropharnyx CancersOropharyngealOropharyngeal CancerOropharyngeal CarcinomaOropharynxOropharynx CancerOropharynx CarcinomaOropharynxsOutcomePD 1PD-1PD-L1PD1PDL-1ParticipantPatientsPatternPenile CancerPersonsPilot ProjectsPopulationPopulation Attributable RisksPrevalencePreventative strategyPrevention strategyPreventive strategyProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1RNARNA ExpressionRNA Gene ProductsResearchResearch SpecimenRibonucleic AcidRiskSCURFINScreening for cancerSiteSpatial DistributionSpecimenSub-Saharan AfricaSubsaharan AfricaT-CellsT-LymphocyteT3 AntigensT3 ComplexT3 moleculeT8 CellsT8 LymphocytesTechnologyTestingTimeTissuesTranscriptionTreatment outcomeTumor-infiltrating immune cellsUterine Cervix CancerViralVirus-HIVVital StatusVulvaVulva CancerVulvar CancerWomanagesanal squamous cell carcinomaanti-cancer therapyattributable fractionbiobankbiological sexbiorepositorycancer carecancer diagnosiscancer disparitycancer health disparitycancer microenvironmentcancer preventioncancer therapycancer-directed therapycancer-related health disparitycausationchemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapyco-infectioncohortcoinfectioncytotoxic T-lymphocyte antigen 4developmentaldisease causationdisparity in cancerdrivingearly cancer detectionenrollexhaustexhaustiongroupingshigh dimensionalityhuman papillomavirus associated malignancyhuman papillomavirus caused cancerhuman papillomavirus driven cancershuman papillomavirus-associated cancerhuman papillomavirus-related cancerhypoimmunityimmune cell infiltrateimmune cell infiltration of tumorsimmune cells infiltrating the tumorimmune cells that infiltrate the tumorimmune deficiencyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunodeficiencyimmunologic substanceimmunological substanceimprovedinfiltration of tumors by immune cellsinnovateinnovationinnovativeintratumoral immune cellintratumoral immune infiltratelow and middle-income countriesmalignancymalignant oropharynx neoplasmmalignant oropharynx tumormenmortalityneoplasm/cancernew approachesnovel approachesnovel strategiesnovel strategyoral pharyngealpenispilot studyprogrammed cell death 1programmed cell death ligand 1programmed cell death protein 1programmed cell death protein ligand 1programmed death 1protein death-ligand 1radio-chemo-therapyradio-chemotherapyradiochemotherapyscreeningscreening cancer patientsscreeningssle2survival outcomesystemic lupus erythematosus susceptibility 2thymus derived lymphocytetooltreatment strategytumortumor immune celltumor immune infiltratetumor infiltration of immune cellstumor microenvironmentunderstudied cancervulval cancervulvarwart virus
Description preview
PROJECT SUMMARY – PROJECT 1 People living with HIV (PLWH) have significantly higher cancer incidence compared to people without HIV for cancers caused by HPV (cervical, vulvar, anal, penile, and oropharyngeal). Altered immunity, not simply immunodeficiency, is one proposed mechanism driving this excess risk and the significantly worse outcomes…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click